Intravenous Recombinant Tissue Plasminogen Activator Therapy for Stroke Patients Receiving Maintenance Hemodialysis: The Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA Registry

Masaki Naganuma(Jichi Medical University), Tomohisa Nezu(Hiroshima University), Noriko Makihara(National Kyushu Medical Center), Masatoshi Koga(National Cerebral and Cardiovascular Center), Ḱazunori Toyoda(National Cerebral and Cardiovascular Center), Mayumi Mori(Kyoto University), Yasushi Okada(National Kyushu Medical Center), Kazuo Minematsu(Kishokai Medical Corporation)
European Neurology
January 1, 2011
10.1159/000328792
Cited by 15

Related Papers

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection
|The Lancet Neurology|2015|464
Carotid Intima-Media Thickness for Atherosclerosis
|Journal of Atherosclerosis and Thrombosis|2015|311
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
|Circulation|2018|245